TriSalus Life Sciences, Inc. Deferred Offering Costs
TriSalus Life Sciences, Inc. (TLSI) had Deferred Offering Costs of $14.16 million as of 2020-12-31, per its 10-K/A filed 2021-12-13.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2023-03-22
- 2020-12-31: Deferred Offering Costs $14.16M.
- 2020-12-22: Deferred Offering Costs $14.16M.
| Period end | Deferred Offering Costs |
|---|---|
| 2020-12-31 | $14.16M 10-K/A · filed 2021-12-13 |
| 2020-12-22 | $14.16M 10-K · filed 2023-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |